www.pfizer.com 
Pfizer
FEBRUARY 16, 2023
These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.
Pfizer
AUGUST 3, 2022
We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures. Learn more about our Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs, and support programs that heighten disease awareness.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 9, 2020
“We have activated our supply chain, most importantly our site in Belgium, and are starting to manufacture so that our vaccine would be available as soon as possible, if our clinical trials prove successful and regulatory approval is granted.”. “As billion doses by the end of 2021. Pfizer Disclosure Notice.
The Pharma Data
NOVEMBER 20, 2020
Pfizer and BioNTech are extremely grateful to the study volunteers and investigative site staff in the clinical trial program, as their involvement was crucial to today’s important milestone in the companies’ efforts to address the COVID-19 global pandemic. as well as Europe, Latin America, and South Africa. About the Study.
The Pharma Data
DECEMBER 2, 2020
We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures. We routinely post information that may be important to investors on our website at www.pfizer.com. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The Pharma Data
MAY 7, 2021
Pfizer and BioNTech initiated the BLA by submitting the nonclinical and clinical data needed to support licensure of the COVID-19 vaccine for use in individuals 16 years of age and older. We routinely post information that may be important to investors on our website at www.Pfizer.com. Pfizer Disclosure Notice.
The Pharma Data
DECEMBER 10, 2020
The ongoing Phase 3 clinical trial of BNT162b2, which is based on BioNTech’s proprietary mRNA technology, has enrolled more than 44,000 participants, the vast majority of whom have received their second dose. We routinely post information that may be important to investors on our website at www.Pfizer.com. About BioNTech.
Expert insights. Personalized for you.
76 
Let's personalize your content